-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Respiratory syncytial virus (RSV) is a common infectious pathogen that can cause seasonal epidemics of lower respiratory tract infections (LRTI), including bronchiolitis and pneumonia, affecting more than 64 million people worldwide each year
.
In the winter, RSV is high, and the development of related therapeutic drugs has also attracted the attention of the industry
.
It is understood that, so far, there is no effective treatment and prevention vaccine specifically for RSV in the world, which also makes most patients face the situation of "no medicines available"
.
But the good news is that with the continuous efforts of researchers in the pharmaceutical industry, this field of drug research and development is ushering in a new situation! In recent years, many multinational pharmaceutical companies have attacked cities in the field of RSV vaccine and innovative drug research and development, and large pharmaceutical giants such as Janssen Pharmaceuticals and Pfizer, as well as local pharmaceutical companies such as Ai Weixin Biopharmaceutical have made new progress
.
For example, in the field of RSV vaccine research and development, in September 2019, Johnson & Johnson’s Janssen Pharmaceuticals announced that the U.
S.
FDA has granted the company a breakthrough drug designation (BTD) for the company’s preventive RSV advanced vaccine for the prevention of diseases caused by the elderly 60 years and older.
Respiratory Syndrome Virus (RSV) mediated lower respiratory tract disease
.
In October 2021, Janssen announced that the vaccine has reached the primary and key secondary endpoints in a phase 2b clinical trial in elderly people over 65 years of age, and its effectiveness in preventing lower respiratory tract diseases is 80%
.
In addition to the vaccine, Sanofi also cooperated with AstraZeneca to develop the monoclonal antibody nirsevimab, which aims to prevent lower respiratory tract infections caused by RSV
.
The drug has been granted breakthrough therapy qualification by the US FDA
.
On September 2, 2021, Pfizer announced that it will start the Phase 3 clinical trial RENOIR of the candidate F subunit vaccine RSVpreF before the bivalent fusion to evaluate the effects of single-dose vaccination on the prevention of respiratory tract in adults 60 years of age or older.
Effectiveness, immunogenicity and safety of syncytial virus (RSV) infection
.
Local innovative drug companies have also begun to join the R&D battle in the RSV vaccine field
.
For example, Ai Diweixin Biopharmaceuticals announced in June this year that the vaccine candidate ADV110 in its research and development pipeline used to prevent diseases caused by respiratory syncytial virus (RSV) infection has successfully completed the first batch of subjects in the Phase II clinical study in Australia
.
The trial is a dual-center, randomized, double-blind, placebo-controlled, dose-exploratory study that recruits healthy subjects aged 60 to 80, and aims to evaluate the safety and immunogenicity of ADV110
.
Previously, Ai Diweixin had completed the phase I clinical trial of ADV110 in Australia.
The results of the study showed that ADV110 has good safety and tolerability in low dose, high dose, as well as single vaccination and double vaccination
.
In the field of RSV therapeutic drug research and development, multinational pharmaceutical companies involved include AstraZeneca/Sanofi, Janssen, etc.
, and local pharmaceutical companies include domestic respiratory system specialist drug developer Aifa Baike.
These companies’ products in research are already in Late clinical stage
.
In addition, there are also MK-1654 from Merck, EDP-938 from Enanta, RV520 from Reviral, and TNM001, a long-acting recombinant RSV antibody from Technolab, which are also in clinical development
.
In general, the current RSV vaccine and drug research and development fields are ushering in a new situation
.
With the advancement of research and development by major pharmaceutical companies in this field, it is expected that in the future, the situation of no medicines for RSV will be solved, which will bring good news to millions of patients and improve the quality of life of patients
.
.
In the winter, RSV is high, and the development of related therapeutic drugs has also attracted the attention of the industry
.
It is understood that, so far, there is no effective treatment and prevention vaccine specifically for RSV in the world, which also makes most patients face the situation of "no medicines available"
.
But the good news is that with the continuous efforts of researchers in the pharmaceutical industry, this field of drug research and development is ushering in a new situation! In recent years, many multinational pharmaceutical companies have attacked cities in the field of RSV vaccine and innovative drug research and development, and large pharmaceutical giants such as Janssen Pharmaceuticals and Pfizer, as well as local pharmaceutical companies such as Ai Weixin Biopharmaceutical have made new progress
.
For example, in the field of RSV vaccine research and development, in September 2019, Johnson & Johnson’s Janssen Pharmaceuticals announced that the U.
S.
FDA has granted the company a breakthrough drug designation (BTD) for the company’s preventive RSV advanced vaccine for the prevention of diseases caused by the elderly 60 years and older.
Respiratory Syndrome Virus (RSV) mediated lower respiratory tract disease
.
In October 2021, Janssen announced that the vaccine has reached the primary and key secondary endpoints in a phase 2b clinical trial in elderly people over 65 years of age, and its effectiveness in preventing lower respiratory tract diseases is 80%
.
In addition to the vaccine, Sanofi also cooperated with AstraZeneca to develop the monoclonal antibody nirsevimab, which aims to prevent lower respiratory tract infections caused by RSV
.
The drug has been granted breakthrough therapy qualification by the US FDA
.
On September 2, 2021, Pfizer announced that it will start the Phase 3 clinical trial RENOIR of the candidate F subunit vaccine RSVpreF before the bivalent fusion to evaluate the effects of single-dose vaccination on the prevention of respiratory tract in adults 60 years of age or older.
Effectiveness, immunogenicity and safety of syncytial virus (RSV) infection
.
Local innovative drug companies have also begun to join the R&D battle in the RSV vaccine field
.
For example, Ai Diweixin Biopharmaceuticals announced in June this year that the vaccine candidate ADV110 in its research and development pipeline used to prevent diseases caused by respiratory syncytial virus (RSV) infection has successfully completed the first batch of subjects in the Phase II clinical study in Australia
.
The trial is a dual-center, randomized, double-blind, placebo-controlled, dose-exploratory study that recruits healthy subjects aged 60 to 80, and aims to evaluate the safety and immunogenicity of ADV110
.
Previously, Ai Diweixin had completed the phase I clinical trial of ADV110 in Australia.
The results of the study showed that ADV110 has good safety and tolerability in low dose, high dose, as well as single vaccination and double vaccination
.
In the field of RSV therapeutic drug research and development, multinational pharmaceutical companies involved include AstraZeneca/Sanofi, Janssen, etc.
, and local pharmaceutical companies include domestic respiratory system specialist drug developer Aifa Baike.
These companies’ products in research are already in Late clinical stage
.
In addition, there are also MK-1654 from Merck, EDP-938 from Enanta, RV520 from Reviral, and TNM001, a long-acting recombinant RSV antibody from Technolab, which are also in clinical development
.
In general, the current RSV vaccine and drug research and development fields are ushering in a new situation
.
With the advancement of research and development by major pharmaceutical companies in this field, it is expected that in the future, the situation of no medicines for RSV will be solved, which will bring good news to millions of patients and improve the quality of life of patients
.
